ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

J. Torres, S. Bonovas, G. Doherty, T. Kucharzik, J.P. Gisbert, T. Raine, M. Adamina, A. Armuzzi, O. Bachmann, P. Bager, L. Biancone, B. Bokemeyer, P. Bossuyt, J. Burisch, P. Collins, A. El-Hussuna, P. Ellul, C. Frei-Lanter, F. Furfaro, C. GingertP. Gionchetti, F. Gomollon, M. Gonzalez-Lorenzo, H. Gordon, T. Hlavaty, P. Juillerat, K. Katsanos, U. Kopylov, E. Krustins, T. Lytras, C. Maaser, F. Magro, J.K. Marshall, P. Myrelid, G. Pellino, I. Rosa, J. Sabino, E. Savarino, A. Spinelli, L. Stassen, M. Uzzan, S. Vavricka, B. Verstockt, J. Warusavitarne, O. Zmora, G. Fiorino*, European Crohn’s Colitis Organisation (ECCO)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

339 Citations (Web of Science)
236 Downloads (Pure)
Original languageEnglish
Pages (from-to)4-22
Number of pages19
JournalJournal of Crohn's & Colitis
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • anti-tnf discontinuation
  • certolizumab pegol
  • double-blind trial
  • evidence-based consensus
  • inflammatory-bowel-disease
  • long-term
  • maintenance therapy
  • metaanalysis comparative efficacy
  • necrosis factor therapy
  • network metaanalysis
  • LONG-TERM
  • METAANALYSIS COMPARATIVE EFFICACY
  • CERTOLIZUMAB PEGOL
  • ANTI-TNF DISCONTINUATION
  • MAINTENANCE THERAPY
  • NETWORK METAANALYSIS
  • INFLAMMATORY-BOWEL-DISEASE
  • EVIDENCE-BASED CONSENSUS
  • DOUBLE-BLIND TRIAL
  • NECROSIS FACTOR THERAPY

Cite this